Despite the increasingly high rate of implantation of cardioverter-defibrillators (ICD) in elderly patients, data supporting their clinical and costeffectiveness in this age stratum are ambiguous and contradictory. We comprehensively reviewed the state-of-the-art data regarding the applicability, safety, clinical-and cost-effectiveness of the ICD in elderly patients, and analysed which patients in this age stratum are more likely to get a survival benefit from this therapy. Although peri-procedural risk may be slightly higher in the elderly, this procedure is still relatively safe in this age group. In terms of correcting potentially life-threatening arrhythmias, the effectiveness of ICD therapy is comparable in older and younger individuals. However, the assumption of persistent ICD benefit in the elderly population is questionable, as any advantage of the device on arrhythmic death may be largely attenuated by a higher total non-arrhythmic mortality. While septuagenarians and octogenarians have higher annual all-cause mortality rates, ICD therapy may remain effective in highly selected patients at high risk of arrhythmic death and with minimum comorbidities despite advanced age. ICD intervention among the elderly, as a group, may not be cost-effective, but the procedure may reach cost-effectiveness in those expected to live .5-7 years after implantation. Biological age rather than chronological age per se should be the decisive factor in making a decision on ICD selection for survival benefit.
Introduction
Implantable cardioverter-defibrillators (ICDs) are a well-established therapy for the prevention of sudden cardiac death (SCD). 1 -7 Studies have shown that .40% of ICDs and cardiac resynchronization therapy (CRT) devices are inserted in individuals ≥70 years of age 8 and 28% of those deemed eligible for ICD implantation by conventional criteria are octogenarians. 9 As the population ages, 10,11 the number of elderly patients considered for ICD implantation is decidedly increasing. However, data supporting the clinical effectiveness of the ICD in this age stratum are ambiguous and sometimes contradictory. 2,12 -18 Although guidelines state that ICD implantation is 'rarely appropriate' in nonagenarians, 19 they do not refer to any specific age limits, but rather to 1-year life expectancy as a mandatory criterion. Octogenarians in particular constitute an understudied segment of those potentially eligible for ICD implantation. The few elderly patients selected for admission into large randomized clinical trials are not usually representative of the real-world elderly population.
We aimed to comprehensively review the current literature regarding the potential benefit of ICDs in the elderly and very elderly population. The applicability of ICD utilization in this age group, its safety, clinical effectiveness, and cost-effectiveness will be thoroughly addressed.
Search strategy
We performed a comprehensive review of scientific data collectable from MEDLINE, EMBASE, and COCHRANE (from inception to May 2014). Studies were selected when addressing the goals of our review: applicability, safety, clinical, and cost-effectiveness of ICD implantation in elderly (.70 -75 years old) and very elderly (.80 years old) patients. Qualitative information was extracted and the reference lists of the accessed full-text articles were further evaluated for sources of potential information relevant to this review.
Rates of cardioverter-defibrillator implantation in the elderly: are older patients well represented in randomized trials and registries?
However, the rate of arrhythmic death was similar between the two groups, resulting in a much lower relative contribution of SCD to all-cause mortality in the elderly group. Almost 20% of elderly patients (≥75 years old) died within 1 year of their episode of lifethreatening ventricular arrhythmias, and at least three-quarters of these deaths were not potentially preventable by an ICD. 18 Grimm et al. 27 followed 500 consecutive ICD patients and concluded that 5-year overall mortality rate was much higher in patients ≥75 vs. ,75 years of age (55 vs. 21%), mostly due to a higher mortality from heart failure. However, Yung et al. 23 observed that, although elderly patients show higher mortality rates after ICD implantation, rates of appropriate shocks are similar across age groups. In this prospective registry of 5399 ICD recipients, rates of appropriate shocks for primary and secondary prevention patients .80 years old were 4.2 events and 11.9 events per 100 person-years, respectively, similar to rates seen in younger patients. Appropriate ICD therapy was successful in terminating the arrhythmia in practically all cases and almost all elderly patients survived . 30 that they had a similar likelihood of receiving appropriate device therapy and therefore they could potentially benefit from the ICD as much as their younger counterparts. 23 In a different study, a similar ventricular tachyarrhythmia burden and number of ICD treatment interventions were observed in 159 patients ,75 years of age vs. 49 who were ≥75. 28 Importantly, a higher mortality rate was seen in the elderly subgroup, almost exclusively of a non-sudden cardiac basis. 28 Thus, in terms of reversing potentially life-threatening arrhythmias, the rationale for ICD therapy is comparable in older and younger individuals. Elderly patients do not seem more susceptible to unsuccessful shocks or electromechanical dissociation after ICD shock. However, an evaluation of the potential benefit of the ICD should not be based on rates of appropriate ICD therapies. Unnecessary, albeit terminologically appropriate, ICD therapy for non-sustained VT is an expanding concern and underlines the need for appropriate ICD programming. In the SCD-HeFT trial, 21% of the patients had appropriate shocks for fast VT or VF, yet the absolute reduction in mortality was only 7.2% at 5 years, 2 while in the DEFINITE trial patients in the ICD group experienced twice as many appropriate shocks than there were fatal events in the control group. 29 The
MADIT-RIT study suggested that inappropriate or unnecessary shocks may in fact potentially increase mortality. The majority of complications were minor for all age groups. Importantly, comorbid conditions such as renal failure, stage IV heart failure, atrial fibrillation or 3rd degree heart block were stronger predictors than age in determining complication risks. Biventricular ICD placement, female gender, physician non-certification and device implantation by non-electrophysiologists were also as important, or even more so, than age in predicting complications. 31 Yung and associates did not show any increase in the frequency of device-related complications within 45 days of implantation across the different age groups (except that younger primary prevention patients had higher inappropriate shock rates). 23 Different studies corroborated these findings, reporting similar rates of procedure-, lead-and pulse generator-related complications between different age groups (including infection, lead failure and lead dislodgement), and a higher risk of inappropriate shocks in younger patients. 27,32 -36 Two large studies and a meta-analysis including randomized controlled trial (RCTs) and observational studies have shown that age is not an independent risk factor for increased ICD-related, operative, in-hospital, or longterm complications (Table 2) . 12, 34, 35 When referring an elderly patient for ICD implantation, physicians need to assess their risk of procedural and post-procedural complications. 31 Based on data from 268 701 ICD implants, Haines et al.
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developed a simple risk score consisting of 10 readily available variables that can accurately identify patients at high and low risk of complications. The risk of any in-hospital complication increased with increasing scores. Although complications in new implants are relatively low in general, they may be potentially increased at the time of generator replacement (4.1-5.8% 38, 39 ). However, detailed data on the risks and predictors of complications in a nationwide cohort in Denmark suggested that ICD generator replacement is less likely to cause complications than the initial device implantation and, in contrast with previous reports, age .80 years was associated with a 20% reduction in complication risk, mostly due to a marked reduction in the frequency of lead-related re-interventions. 40 Clinical effectiveness: does the elderly implantable cardioverter-defibrillator recipient live longer?
Estimate of the overall survival in elderly patients receiving ICDs: interaction age/ survival
Heart failure patients express meaningful preferences about quality vs. length of life, with younger patients preferring increased survival whereas older patients often consider quality of life (QoL) of greater importance. 41 Although a discussion of the potential benefit of the ICD in elderly patients should not be limited to a comparison of mortality rates with vs. without the ICD, all-cause mortality is usually the most robust and easily assessed endpoint. Observational studies have previously assessed survival of elderly patients following ICD implantation, 23, 33, 42, 43 whereas the first assessment of survival in octogenarians following ICD generator replacement was much more recent. 25 Koplan et al. 42 After controlling for potential confounders and comorbidities, age at ICD implantation remained strongly associated with subsequent total, cardiac, and non-cardiac mortality. Importantly, divergence in survival occurred early and continued to increase throughout the follow-up time. The authors concluded that age itself should be considered a comorbidity when deeming appropriateness of ICD implantation, as it exerts an effect on mortality independent of baseline co-morbidity data. 43 Van Rees et al. 33 23 This study also suggested that death after appropriate shock is highest among elderly primary and secondary prevention patients (after an appropriate shock, the adjusted hazard ratios for death per decade were 1.28 and 1.34 for primary and secondary prevention, respectively). In our analysis of all ICD-related procedures carried out in octogenarian patients at our hospital between November 1991 and May 2012, we found the median additional years of life after ICD implantation in patients who died before data retrieval was 2.5, and 65% of deceased patients after ICD implantation died in the first 3 years after the procedure. 25 A different study concluded that mortality of patients ≥75 years old was similar to that of the age-matched general population irrespective of delivery of ICD therapy. 44 Conversely, Duray et al. 32 concluded that elderly ICD recipients had comparable survival rates and appropriate use of the ICD compared with younger individuals. The median survival of elderly ICD recipients should be taken into account. Taken as a whole, the overall life expectancy of octogenarians in the USA is 8 years, which is two-fold greater than that observed in octogenarian ICD recipients in the study by Koplan et al. 42 Prior data reported 1-and 5-year survival of 80 and 40%, respectively, in octogenarians following pacemaker implantation, 45 and a 1-year mortality of 11.1 and 8.1% for elderly patients (age [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] with chronic coronary artery disease treated invasively or conservatively, respectively.
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Subgroup analyses of the main implantable cardioverter-defibrillator trials and/or meta-analyses Evidence in favour of implantable cardioverter-defibrillator implantation in the elderly A sub-group analysis of the MADIT-II trial revealed a 0.56 hazard ratio (95 CI 0.29 -1.08, P ¼ 0.08) for the mortality risk in patients ≥75 years assigned to defibrillator implant compared with those in conventional therapy after a mean follow-up of 17.2 months (comparatively, the hazard ratio in patients ,75 years assigned to defibrillator implant was 0.63 after 20.8 months, CI 0.45-0.88, P ¼ 0.01). 13 Few differences in sub-group characteristics were observed between patients ,75 and ≥75 years old, suggesting a highly careful selection of elderly patients qualifying for ICD treatment. It is noteworthy that, in the original MADIT-II trial, the survival curves between ICD and medical therapy-only subjects did not begin to diverge until 9 months after implant. 1 In a prospective cohort study of 965 patients with ischaemic and non-ischaemic cardiomyopathies, severe LV dysfunction and no prior ventricular arrhythmias, a comparison was made between long-term mortality in patients who did vs. did not receive ICDs over a mean follow-up period of 34 + 16 months. Although both the groups were similar in age and prevalence of most major comorbid conditions, ICD therapy was associated with a 31% lower risk for allcause mortality, a mortality benefit similar to those seen in primary 16.1% ≥ 80 years old) † Occurrence of any peri-procedural adverse event or in-hospital death increased from 2.8% in the youngest age group (,65 years) to 4.5% in the oldest age groups (≥80 years) † Renal failure, stage IV heart failure, atrial fibrillation, third degree heart block, biventricular ICD placement, female gender, physician non-certification and device implantation by non-electrophysiologists were stronger predictors of complications than age
Yung et al. Evidence against cardioverter-defibrillator implantation in the elderly The benefit of the ICD in primary prevention of SCD, according to MADIT II and SCD-HeFT, emerges only in a mid-to long-term follow-up (2 -5 years). 16 Given that the median survival of elderly patients with an ICD has been shown to be less than 5 years in most studies, 25, 33, 42, 43 the effectiveness of the ICD in prolonging their lives seems marginal. The SCD-HefT trial failed to demonstrate improved survival in patients ≥65 years, and survival in the overall cohort was essentially the same for ICD and non-ICD patients alike for the first 18 months of follow-up. 2 A meta-analysis by Santangeli et al had reported on pooled data of the DEFINITE, SCD-HeFT, and MADIT trials, but was unable to demonstrate significant survival benefit of the ICD in the elderly. 17 A different metaanalysis pooled individual patient data from all three secondary prevention trials comparing ICD to amiodarone (AVID, CIDS and CASH) and concluded that ICD therapy did not seem to offer a survival benefit in secondary prevention patients ≥75 years of age. 18 The AVID trial showed an unadjusted average of only 2.7 months of additional life gained at 3 years in a cohort of patients with mean age of 65.
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Selecting the patient for the procedure: which elderly patients to consider for an ICD?
A previous study has shown that there is no significant difference in survival between clinical trial patients (MADIT-II and SCD-HeFT) randomized to receive an ICD and a similar group of clinical registry patients who received a primary prevention ICD, despite the fact the latter are significantly older and have more comorbidities. These results held even after limiting the analyses to patients 65 years and older. However, criticisms exist regarding the exclusion of many patients from analysis, stating that the clinical registry subgroup did not resemble a true cohort of patients in real-life practice. 47 Although there are many elderly patients in whom implantation of an ICD is not appropriate because of comorbidities that may shorten life expectancy, Koplan et al. 42 have shown that a proportion of elderly patients may survive for ≥4 years after ICD implant. As the low-ejection fraction group has considerable risk heterogeneity, and multiple parameters may influence the risk of arrhythmic mortality among patients with similar degrees of left ventricular dysfunction, identification of those patients at high risk of early mortality who may not derive any benefit from ICD implantation is essential for optimal patient management. While patients with no risk factors were shown to experience relatively low 2-year mortality rates without an ICD, thereby limiting a meaningful ICD effect within this time period, very high-risk patients (defined by urea levels ≥50 mg/dL and/or serum creatinine ≥2.5 mg/dL) had 2-year mortality rates close to 50%, with or without an ICD, and the predominant mode of death in this population was non-arrhythmic in nature. Implantable cardioverter-defibrillator therapy was associated with a 49% reduction in the risk of death among patients with one to two risk factors, while in patients with three risk factors or more mortality was only slightly lower in the ICD group than in the conventional therapy group (29 vs. 32%). 48 This risk score was subsequently validated in a longterm follow-up 49 and a cohort of elderly patients.
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(ii) In their cohort of patients with an ICD, Chong et al. 52 have
shown that those with clinical markers involving two or more organ systems had a 38% 1-year mortality rate despite the ICD. (iii) Based on .45.000 primary prevention ICD patients (of which 40% were ≥75 years of age), Bilchick et al. developed a model ('SHOCKED') that accurately identified patients at highest risk of death after ICD implantation. 53 In MADIT-II   1 and SCD-HeFT, 2 the 20% of patients with the highest predicted mortality rates after ICD implantation did not derive a survival benefit from ICD implantation. With this in mind, it was noteworthy that the 58% 3-year mortality rate for registry patients in the highest nomogram-based quintile of risk 53 was even higher than the 3-year mortality rate for ICD patients in the highest risk quintile (42%) from the SCD-HeFT analysis. 59 and previous heart failure hospitalizations 60 in ICD recipients. In regards to heart failure, a study by Eho et al suggested that women with this comorbidity have lower mortality than men, and fewer of those deaths are sudden throughout a spectrum of all-cause mortality risk.
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Procedural aspects: what device and implantable cardioverter-defibrillator programming?
The use of a single-chamber device and ICD programming to ventricular backup pacing at 40 b.p.m. should be strongly considered should there be no indication for pacing. 62, 63 However, the need to minimize right ventricular pacing is not age-specific. The PREPARE, 64 MADIT-RIT, 30 and ADVANCE-III 65 studies and two very recent meta-analyses 66, 67 have clearly shown that programming high-rate and/or delayed therapy associates with reductions in unnecessary ICD therapy and may eventually decrease all-cause mortality. 30 This may be relevant to the elderly population, as a subgroup analysis of the MADIT-RIT trial suggested that patients .65 years old had the largest survival benefit from high-rate ICD therapy. 30 Also, a lower threshold for CRT implantation without defibrillator backup in the primary prevention elderly patient should perhaps be considered in light of recent evidence, suggesting that (i) CRT-D does not offer additional survival advantage over CRT-P at longer term follow-up, despite a trend at 1 year favouring the former; 68 (ii) there is no survival benefit from CRT-D (vs. CRT-P) in patients deemed non-responders to CRT, 68 and (iii) the association between advanced age and adverse clinical outcomes (heart failure, death, and appropriate ICD therapy) is attenuated in elderly patients implanted with CRT-D devices compared with ICD only. 69 When elderly patients with heart failure are at high risk of non-sudden mortality because of a high comorbidity burden, 70 a CRT-P device rather than a CRT-D may be justified as symptomatic improvement and enhanced QoL are probably more relevant than reducing the risk of arrhythmic mortality. It should be noted that two previous studies have suggested that catheter ablation of ventricular tachycardia in elderly patients with structural heart disease is a relatively safe and effective procedure. 71, 72 It is reasonable to consider VT ablation as an alternative to the ICD in elderly patients who refuse ICD implantation or whose life expectancy is limited. Figure 1 highlights the frequent dilemmas involved in the decision to give elderly patients an ICD, while Figure 2 lists the main similarities and differences between elderly patients and other age groups.
Implantable cardioverterdefibrillator generator replacement at the end of battery life: is there any evidence of benefit in the very elderly?
There are no current formal recommendations to guide physicians when elderly patients with ICDs require elective unit replacement (EUR).
Can we extrapolate the results of trials supporting the guidelines to this population?
Are there specific elderly groups with higher benefit? Some risk classifications have been proposed [49] [50] [51] [52] [53] [54] [55] , but an ultimate score providing strong support for implanting in some patients while excluding others is still lacking How old is too old?
Neither this aspect, nor the issure of the existence of a clear cutoff value for defining elderly and very elderly have yet been clarified: inexistent evidence
Is it cost-effective? For all patients?
ICDs are not cost-effective in elderly patients as a group, but may be a cost-effective therapy when the patient has a longevity of ≥7 years or one ICD battery life: moderate evidence 85, 86 Is there a benefit from ICD replacement at the end of battery life?
The benefit in elderly patients without previous ICD therapies may be marginal: weak evidence 75, 76 Is there a benefit from specific devices and/or programming?
Therapy reduction programming results in significant and consistent reduction in all-cause mortality in the overall ICD population, but this question has not been specifically addressed in the elderly: weak evidence 66 When should therapies be disabled?
This should occur after a combined patient and/or family (if the patient is unable to decide) decision Consensus / Not evidence-based Does it improve survival?
Mortality is higher in elderly: strong evidence 24, 26, 34, 43, 44 However, there may be a survival benefit in selected individuals: weak evidence [12] [13] [14] What is the risk of peri-and postprocedural complications? In our analysis of all ICD-related procedures carried out in octogenarians at our hospital between November 1991 and May 2012, 25 we reported the median additional years of life after ICD EUR in patients who died before data retrieval was 1.2, and 50% of deceased patients died within the first year. Ventricular tachycardia occurred in a small minority of patients after EUR and no VF events were reported. Importantly, ICD therapies were not delivered in patients who had not had ICD interventions before the EUR. 25 A very recent study reported 1-, 3-, and 5-year mortality rates of 9.8, 27.0, and 41.2%, respectively, in 111.826 patients from the NCDRw ICD Registry TM following ICD generator replacement. Older age, atrial fibrillation, congestive heart failure, chronic lung disease, cerebrovascular disease, diabetes, and renal dysfunction predicted worse survival. 73 In a different study, at least 26% of 231 patients admitted for ICD generator replacement no longer met guideline indications for an ICD (indications for continued ICD therapy were defined as EF , 35% or receipt of appropriate device therapy) 74 and subsequently received appropriate ICD therapies at a significantly lower annual rate compared with patients who did (2.8 vs. 10.7%). 74 These studies may question the applicability of ICD generator replacement in very elderly patients with no history of appropriate ICD therapies and support the need for re-evaluation of the LV EF prior to unit replacement, and eventually perform ICD explant, rather than generator replacement, in those without previous appropriate ICD therapies and with significant improvement of LV systolic function. Importantly, the risk of appropriate ICD therapy and/or rapid ventricular arrhythmia, albeit persisting over time, decreases significantly over the years. 75 In octogenarians who are due for an ICD EUR, several arguments can be made for either: 18, 27, 29 • Appropriate therapies may occur more frequently preceding non-arrhythmic death, not impacting on overall survival 18 • Higher peri-procedural complication rates (contradicting results) 32 • Lower rate of inappropriate shocks 24, 34 • Lower life expectancy 24, 26, 34, 43, 44 • ICDs seem ineffective or only marginally effective in reducingall-cause mortality in the elderly, as a group (contradicting results) 2, 16, 17, 18, 26, 34, [43] [44] [45] • Patient selection and comorbidity assessment may play a much more important role • Longevity of leads may be a less important issue (give the lower life expectancy of the elderly patient) • May need backup pacing more frequently • One battery-life may be enough in most patients (as average median survival does not exceed 5 years in most studies) 26, 34, 43, 44 • Elderly may benefit from less aggressive ICD programming (inference,
give their higher degree of comorbidity and frailty) [65] [66] [67] [68] [69] • They seem to value quality of life over longevity 42 • Ethical issues when performing elective generator replacement • ICDs may interfere with the natural process of dying peacefully 83 • Elderly more frequently demand therapy deactivtion when approaching the end of life • ICDs may be less cost-effective, namely if the patient does not outlive the battery 85, 86 Figure 2 Use of ICDs in the elderly: points to consider in decision-making. ICD, implantable cardioverter-defibrillator; RCT, randomized controlled trial.
ICD Implantation in the elderly
Downgrading the implantable cardioverter-defibrillator to a standard pacemaker (if pacing support needed), explanting the device or simply not replacing it at all
Mortality is high in the first few years following ICD generator replacement. 25, 73 Patients who demonstrate recovery of LV function from CRT or medical therapy may be at lower risk of arrhythmic mortality when compared with the pre-procedural estimated risk 76 • Some ICD patients whose EF has improved to >35% at the time of generator replacement remain at risk for appropriate ICD shocks 84 • More than one fifth of ICD patients without prior appropriate ICD therapy still receive appropriate ICD intervention whithin 3 years of generator replacement 79 • As some individuals get used to a psychological sense of security from their device, they may find it traumatizing to manage without it
• Future treatments developed for heart failure and other non-cardiac medical conditions may eventually reduce their risk of non-sudden death Downgrading the ICD to a standard pacemaker (if pacing support is needed) or simply not replacing it at all
• High mortality rates in the first few years following ICD generator replacement, especially in those with multiple comorbidities 26, 75 • At least ¼ of patients no longer meet guideline indications for an ICD at time of unit replacement. These patients subsequently receive appropriate ICD therapies at a significantly lower annual rate 76 • Patients who demonstrate recovery of LV function from CRT or medical therapy may be at lower risk of arrhythmic mortality when compared to the pre-procedural estimated risk 77 • The risk of appropriate ICD therapy and/or rapid ventricular arrythmia, albeit persisting over time, decreases significantly over the years 77 • With increasing age, some patients may feel differently towards their final mode of death and may wish to have their device deactivated
• ICD generator replacement implies a 4-6% risk of major peri-and post-procedural complications [80] [81] [82] • ICDs may interfere with the natural process of dying peacefully 83 • ICD generator replacement in the elderly, as a group, is hardly cost-effective 85, 86 Figure 3 Implantable cardioverter-defibrillator generator replacement in the elderly: points to consider in decision-making. ICD, implantable cardioverter-defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia; LV, left ventricular; CRT, cardiac resynchronization therapy.
S. Barra et al.
resuscitate order still had shock therapy programmed 'on' at 24 h before death, which allowed for the delivery of shock treatment in almost one-fourth of them ( Figure 3) .
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Replacing the device generator
It would be unethical not to replace the ICD generator at end of battery life in elderly patients with previous appropriate ICD therapy for VF or fast VT, unless requested by the patient. Some ICD patients whose EF has improved to .35% at the time of ICD generator replacement remain at risk for appropriate ICD shocks 82 and up to 21.4% of ICD patients without prior appropriate ICD therapy may still receive appropriate ICD intervention within 3 years of generator replacement ( Figure 3 ).
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Cost-effectiveness: is it cost-effective to give elderly patients an implantable cardioverter-defibrillator?
With the expansion of the population eligible for an ICD, resource limitations and discussions of cost-effectiveness have come to the forefront. The cost-effectiveness of the ICD in routine clinical practice seems less obvious in certain sub-groups of patients, particularly in the case of elderly patients who are at higher risk of non-arrhythmic death.
As most costs associated with ICD implantation occur in the early phase of treatment, cost-effectiveness may become more favourable as patients live longer, the battery life of ICDs extends, cost of the device is reduced and improvements to efficacy occur (improved patient selection, minimized unnecessary shock). Patient longevity increases the cost-effectiveness of the ICD. In the MADIT-II trial, 1 the number needed to treat to prevent one additional primary outcome decreased from 17 at the end of the first 2 years to 8 when follow-up was extended to 8 years.
On the basis of data from eight large primary prevention trials, the incremental cost-effectiveness of prophylactic ICD therapy has been estimated to range from $34.000 to $70.200 per quality-adjusted life year (QALY) added. 83 The authors claimed that costs would remain ,$100 000 per QALY as long as mortality was reduced for ≥7 years, with estimated costs escalating quickly as the duration of efficacy was reduced. If the survival time horizon was reduced to 5 years after ICD implantation, as in patients ≥75 years described by Pelligrini et al., 43 cost estimates would vary between $90.000 and $250.000. Though a single threshold for cost-effectiveness has not been properly established, values ranging from $50.000 to $120.000 per QALY have been proposed. 84 In this context, it is highly relevant that the average median survival of elderly ICD recipients (≥75 years old) does not seem to surpass the 5-year mark in most studies, 25, 33, 42, 43 with much shorter lifespan in patients with multiple comorbidities. In fact, current data do not support the assumption that ICD therapy has a persistent effect on late survival. A meta-analysis of secondary prevention trials showed a convergence of survival curves for ICD and control arms at 4 years and a life extension of just 4.4 months over a follow-up period of 6 years, 85 while patients receiving appropriate shocks in the SCD-HeFT and MADIT-II studies had a poor short-term prognosis. 86, 87 In the latter, based on an average survival gain of only 2 months and a three-fold higher rate of hospitalizations, the incremental cost-effectiveness ratio was $235.000 per year of life saved, unadjusted for QoL. 88 A similar finding was reported from the CIDS trial in secondary prevention. 89 Thus, ICD intervention among the elderly, as a group, may not be cost-effective. To reach costeffectiveness in the elderly, limiting their application to those expected to live .5 years after implantation, or rather one ICD battery-life, would be necessary. An important aspect of cost-effectiveness is the assessment of the impact on QoL. In the case of ICD therapy, evidence remains conflicting and relatively weak. The only study examining the relationship between age and QoL in the setting of a RCT was a MADIT-II substudy that found no significant differences in QALY between control and ICD groups and between patients younger and older than 65. 90 The largest QoL study in ICD recipients for primary prevention of SCD was performed in the SCD-HeFT population, yet the effect of age on QoL was not examined. In fact, there is little QoL data on the use of ICDs in elderly patients, which is a paradox as QoL is often a critical factor in clinical decision-making in the elderly. However, while older patients with ICDs have decreased physical functioning, more co-morbid illness, and worse symptoms that negatively impact QoL, younger patients with ICDs tend to experience increased psychological distress, anxiety, and depression. 91, 92 Implantable cardioverter-defibrillator impact on QoL goes much beyond the deleteriously impact of recurrent or unnecessary shocks. Reynolds et al. 34 found one or more complications in 11% of the procedures which were associated with highly significant increase in the length of hospital stay (1-10 days) and hospital costs ($5.000-$20.000). Also, recent data suggest that device-related infection increased by 1% in the last decade, reaching 2.41% of all implants in 2008. 93 The hospitalization of elderly patients tends to be more prolonged and susceptible to clinical intercurrences and thus more costly.
Conclusions
Implantable cardioverter-defibrillatorimplantation may reduce mortality in the elderly, but it should be recognized to constitute a smaller absolute clinical benefit. Termination of ventricular arrhythmias by ICD therapies could prevent sudden death, but probably results in a marginal prolongation of life, due to high competing risk for non-SCD. Alongside with the expensive cost, the possibility of adversely affecting QoL and increasing comorbidity burden may lead to difficulties in justifying this therapy in the elderly population. Nevertheless, in those very well-selected elderly patients at high risk of arrhythmic death and with minimum comorbidities despite advanced age, ICD intervention may reduce mortality to near age-specific life-expectancy. Therefore, biological age (possibly assessed through a multivariable score, which is yet to be optimized) rather than chronological age per se should be the decisive factor in making a decision on ICD selection for survival benefit.
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